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lecular weight and substitution versus other fluids for non-
septic patients, He et al. [1] did not confirm the increased
mortality, renal replacement therapy (RRT), bleeding and
red blood cell transfusions seen in sepsis. A favourable
safety profile for 6 % HES solutions was suggested.
He et al. stated that Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines were followed, yet the meta-analysis lacked
tests of interaction to compare different HES solutions
and pre-specified subgroup analyses. The discussed limita-
tions of the meta-analysis included study quality, hetero-
geneity, and problematic use [2] of gelatin as a control
fluid. The Cochrane Collaboration Risk-of-Bias Tool was
cited for guidance in the assessment of study quality,
where any use of scales for risk of bias is explicitlydiscouraged because summary scores have been shown to
be unreliable. He et al. calculated summary scores using a
nonvalidated modified Jadad scale [3] where the highest
possible score is 8, but the highest possible summary score
for He et al. was only 7; reasons for this difference are
obscure. Information on how assessment of risk of bias
was actually performed is missing. For selective outcome
reporting, the study by James et al. was wrongly judged as
‘low risk’ although ‘high risk’ had been identified previ-
ously [4, 5].
The key message from He et al. that 6 % HES does
not seem to increase mortality or RRT incidence in
nonseptic ICU patients is speculative because assess-
ment of the study quality is insufficient. HES should
be considered unsafe in all ICU patients until proven
contrary in high-quality studies.We thank Dr Bayer and Dr Reinhart for their comments,
which we would like to nuance.
Recently, Myburgh et al. [6] reported that there was
no significant difference in 90-day mortality between
patients resuscitated with 6 % HES or saline. Another
international multicentre large-sample randomised
controlled trial (RCT) also reported the use of colloids
(including HES, gelatin, dextran and albumin) versus
any crystalloids for volume expansion therapy to decrease
90-day mortality [7]. In addition, two meta-analyses also
showed that HES did not increase mortality or renal injury
in subgroup analyses of nonseptic patients [8, 9]. Our
meta-analysis also obtained similar results.We had pre-specified subgroup analyses by different
molecular weight of 6 % HES, risk of bias assessment and
different kinds of fluids, all of which were found with no
significant difference in mortality. We also made a brief
analysis about the limitations of the meta-analysis. The
Cochrane Collaboration Risk-of-Bias Tool and the modified
Jadad scale were both always used for assessing the risk of
bias [3, 8]. We apologise for the clerical error regarding the
highest possible score in the modified Jadad scale and the
inappropriate judgement for selective outcome reporting of
the study by James et al.
Owing to the limitation of the current RCTs, our
conclusion did not suggest using HES for these patients,
and advised further RCTs of high quality for further
study.article is distributed under the terms of the Creative Commons Attribution 4.0
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Competing interests
OB received speaker’s fees from CSL Behring, Germany. KR received an
unrestricted research grant to conduct the VISEP trial and consultancy fees
from B Braun Melsungen. The remaining authors declare that they have no
competing interests.
Authors’ contributions
KR and OB drafted the manuscript. Both authors read and approved the final
manuscript.
Author details
1Department of Anaesthesiology and Intensive Care, Jena University Hospital,
Erlanger Allee 101, 07747 Jena, Germany. 2Department of Anaesthesiology
and Intensive Care, Center for Sepsis Control and Care, Chairman Global
Sepsis Alliance, Jena University Hospital, Erlanger Allee 101, 07747 Jena,
Germany.
References
1. He B, Xu B, Xu X, Li L, Ren R, Chen Z, et al. Hydroxyethyl starch versus other
fluids for non-septic patients in the intensive care unit: a meta-analysis of
randomized controlled trials. Crit Care. 2015;19:92.
2. Thomas-Rueddel DO, Vlasakov V, Reinhart K, Jaeschke R, Rueddel H,
Hutagalung R, et al. Safety of gelatin for volume resuscitation—a systematic
review and meta-analysis. Intensive Care Med. 2012;38:1134–42.
3. Bañares R, Albillos A, Rincón D, Alonso S, González M, Ruiz-del-Arbol L, et al.
Endoscopic treatment versus endoscopic plus pharmacologic treatment for
acute variceal bleeding: a meta-analysis. Hepatology. 2002;35:609–15.
4. Finfer S. Hydroxyethyl starch in patients with trauma. Br J Anaesth.
2012;108:159–60.
5. Reinhart K, Hartog CS. Hydroxyethyl starch in patients with trauma. Br J
Anaesth. 2012;108:321–2.
6. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al.
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl
J Med. 2012;367:1901–11.
7. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, et al. Effects of
fluid resuscitation with colloids vs crystalloids on mortality in critically ill
patients presenting with hypovolemic shock: the CRISTAL randomized trial.
JAMA. 2013;310:1809–17.
8. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall
JC, et al. Association of hydroxyethyl starch administration with mortality
and acute kidney injury in critically ill patients requiring volume
resuscitation: a systematic review and meta-analysis. JAMA. 2013;309:678–88.
9. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid
therapies: effects on kidney function. Cochrane Database Syst Rev.
2013;7:CD007594.
